Loading clinical trials...

Study of VIR-2482 in Healthy Volunteers | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Study of VIR-2482 in Healthy Volunteers

A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of VIR-2482 for the Prevention of Influenza A Illness

NCT04033406•Vir Biotechnology, Inc.

View on ClinicalTrials.gov

Summary

This is a phase 1 study in which healthy volunteers will receive VIR-2482 or placebo and will be assessed for safety, pharmacokinetics, and immunogenicity of VIR-2482 in preventing Influenza A illness.

Eligibility

Age

18 - 64 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Healthy Male or Female age 18 to \< 65 years
•Body mass index (BMI) of 18.0 kg/m\^2 to 32.0kg/m\^2

Exclusion Criteria

•Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation
•History of influenza-like illness or confirmed influenza infection within 3 months prior to randomization.
•Fever-like illness within 5 days of randomization.
•History or clinical evidence of conditions considered high risk for developing influenza-related complications.

Locations (1)

Investigative Site

Brisbane, Queensland, Australia

Key Dates

Start Date

August 26, 2019

Primary Completion Date

November 1, 2021

Completion Date

November 1, 2021

Last Updated

June 9, 2022

Enrollment

100

ACTUAL participants

Conditions

Influenza A

Interventions

VIR-2482

DRUG

Placebo

DRUG

A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

NCT07128615

Influenza A

View study

ACTIVE_NOT_RECRUITINGPHASE1

Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®

NCT04896853

COVID-19 Acute Respiratory Distress SyndromeInfluenza A+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 9, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of VIR-2482 in Healthy Volunteers

Inclusion Criteria

Exclusion Criteria

A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®

Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

CC-42344 Safety Study in Healthy Participants

Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations

Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings